Inflammatory biomarker C-reactive protein and radiotherapy-induced early adverse skin reactions in patients with breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 9, 2014, Pages 1873-1883

  Rodriguez Gil, Jorge L ^a   Takita, Cristiane ^a,b   Wright, Jean ^a,b   Reis, Isildinha M ^a,b   Zhao, Wei ^a   Lally, Brian E ^a,b   Hu, Jennifer J ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

ADULT; ADVERSE OUTCOME; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; ETHNIC DIFFERENCE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MIDDLE AGED; QUALITY OF LIFE; RACE DIFFERENCE; SKIN TOXICITY; TREATMENT OUTCOME; ADJUVANT THERAPY; ADVERSE EFFECTS; BLOOD; BREAST NEOPLASMS; DISEASE COURSE; METABOLISM; NEOPLASMS, RADIATION-INDUCED; PATHOLOGY; PILOT STUDY; RADIATION INJURIES; RADIATION RESPONSE; SKIN; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, RADIATION-INDUCED; PILOT PROJECTS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; SKIN;

EID: 84907172354     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0263     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: A Cancer J Clin 2014; 64: 9-29.
2. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 2011; 378: 1707-16.
3. Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008; 26: 2085-92.
4. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer 2008; 44: 2587-99.
5. Poortmans PM, Collette L, Horiot JC, Van den BogaertWF, Fourquet A, Kuten A, et al. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol 2009; 90: 80-5.
6. Buchholz TA. Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med 2009; 360: 63-70.
7. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. TheUKStandardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086-94.
8. Raabe A, Derda K, Reuther S, Szymczak S, Borgmann K, Hoeller U, et al. Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiat Oncol (London, England) 2012; 7: 65.
9. Tanteles GA, Murray RJ, Mills J, Barwell J, Chakraborti P, Chan S, et al. Variation in telangiectasia predisposing genes is associated with overall radiation toxicity. Int J Radiat Oncol Biol Phys 2012; 84: 1031-6.
10. Terrazzino S, La Mattina P, Gambaro G, Masini L, Franco P, Canonico PL, et al. Common variants of GSTP1, GSTA1, and TGFb1 are associated with the risk of radiation-induced fibrosis in breast cancer patients. Int J Radiat Oncol Biol Phys 2012; 83: 504-11.
11. Gallet P, Phulpin B, Merlin JL, Leroux A, Bravetti P, Mecellem H, et al. Long-term alterations of cytokines and growth factors expression in irradiated tissues and relation with histological severity scoring. PLoS ONE 2011; 6: e29399.
12. Citrin DE, Hitchcock YJ, Chung EJ, Frandsen J, Urick ME, Shield W, et al. Determination of cytokine protein levels in oral secretions in patients undergoing radiotherapy for head and neck malignancies. Radiat Oncol (London, England) 2012; 7: 64.
13. Pfutzner A, Schondorf T, Hanefeld M, Forst T. High-sensitivity Creactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol 2010; 4: 706-16.
14. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011; 48: 155-70.
15. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetes Care 2013; 36: 166-75.
16. Liu L, Mills PJ, RisslingM, Fiorentino L, Natarajan L, Dimsdale JE, et al. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun 2012; 26: 706-13.
17. Alfano CM, Imayama I, Neuhouser ML, Kiecolt-Glaser JK, Smith AW, Meeske K, et al. Fatigue, inflammation, and omega-3 and omega-6 fatty acid intake among breast cancer survivors. J Clin Oncol 2012; 30: 1280-7.
18. Mohammed FF, Poon I, Zhang L, Elliott L, Hodson ID, Sagar SM, et al. Acute-phase response reactants as objective biomarkers of radiationinduced mucositis in head and neck cancer. Head Neck 2012; 34: 985-93.
19. Zeng YC, Xue M, Chi F, Xu ZG, Fan GL, Wu R, et al. C-reactive protein level predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. Tumour Biol 2012; 33: 891-5.
20. Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, Todo M, et al. Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 2011; 103: 62-8.
21. Ryan JL, BoleC, Hickok JT, Figueroa-Moseley C, Colman L, KhannaRC, et al. Post-treatment skin reactions reported by cancer patients differ by race, not by treatment or expectations. Br J Cancer 2007; 97: 14-21.
22. Hamama S, Gilbert-Sirieix M, Vozenin MC, Delanian S. Radiationinduced enteropathy: molecular basis of pentoxifylline-vitamin E antifibrotic effect involved TGF-b1 cascade inhibition. Radiother Oncol 2012; 105: 305-12.
23. Mukesh M, Harris E, Jena R, Evans P, Coles C. Relationship between irradiated breast volume and late normal tissue complications: a systematic review. Radiother Oncol 2012; 104: 1-10.
24. Nazmi A, Victora CG. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health 2007; 7: 212.
25. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. JAm Coll Cardiol 2005; 46: 464-9.
26. Brown MD, Feairheller DL, Thakkar S, Veerabhadrappa P, Park JY. Racial differences in tumor necrosis factor-a-induced endothelial microparticles and interleukin-6 production. Vasc Health Risk Manag 2011; 7: 541-50.
27. Park NJ, Kang DH. Inflammatory cytokine levels and breast cancer risk factors: racial differences of healthy Caucasian and African American women. Oncol Nurs Forum 2013; 40: 490-500.
28. Ho AY, Fan G, Atencio DP, Green S, Formenti SC, Haffty BG, et al. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phy 2007; 69: 677-84.